Neumora Therapeutics, Inc. Common Stock (NMRA)
Automate Your Wheel Strategy on NMRA
With Tiblio's Option Bot, you can configure your own wheel strategy including NMRA - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol NMRA
- Rev/Share 0.0
- Book/Share 1.4144
- PB 0.5585
- Debt/Equity 0.0041
- CurrentRatio 8.9792
- ROIC -1.1977
- MktCap 127780857.0
- FreeCF/Share -1.2304
- PFCF -0.6432
- PE -0.4943
- Debt/Assets 0.0037
- DivYield 0
- ROE -0.8479
- Rating B-
- Score 3
- Recommendation Neutral
- P/E Score 1
- DCF Score 4
- P/B Score 4
- D/E Score 4
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | NMRA | BofA Securities | Buy | Underperform | -- | $1 | April 2, 2025 |
| Downgrade | NMRA | William Blair | Outperform | Market Perform | -- | -- | March 10, 2025 |
| Downgrade | NMRA | Guggenheim | Buy | Neutral | -- | -- | March 7, 2025 |
| Downgrade | NMRA | Stifel | Buy | Hold | $6 | $2 | March 7, 2025 |
| Downgrade | NMRA | RBC Capital Mkts | Outperform | Sector Perform | $29 | $4 | Jan. 2, 2025 |
| Initiation | NMRA | H.C. Wainwright | -- | Buy | -- | $30 | Oct. 1, 2024 |
News
ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Neumora Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – NMRA
Published: February 13, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Feb. 13, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of the common stock of Neumora Therapeutics, Inc. (NASDAQ: NMRA) pursuant and/or traceable to the registration statement and related prospectus (collectively, the “Offering Documents”) issued in connection with Neumora's September 2023 initial public offering (the “IPO”). If you wish to serve as lead plaintiff, you must move the Court no later than April 7, 2025.
Read More
Lost Money on Neumora Therapeutics, Inc.(NMRA)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky
Published: February 13, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 13, 2025 / If you suffered a loss on your Neumora Therapeutics, Inc. (NASDAQ:NMRA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/neumora-therapeutics-inc-lawsuit-submission-form?prid=129426&wire=1 or contact Joseph E. Levi, Esq.
Read More
NMRA Investor Reminder: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Deadline in Securities Fraud Class Action Lawsuit Filed Against Neumora Therapeutics, Inc.
Published: February 13, 2025 by: GlobeNewsWire
Sentiment: Neutral
RADNOR, Pa., Feb. 13, 2025 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP ( www.ktmc.com ) informs investors that a securities class action lawsuit has been filed in the United States District Court for the Southern District of New York against Neumora Therapeutics, Inc. (“Neumora”) ( NASDAQ: NMRA ) on behalf of those who purchased or otherwise acquired Neumora common stock pursuant and/or traceable to Neumora's prospectus and registration statement (collectively, the “Offering Documents”) issued in connection with Neumora's initial public offering held on or around September 15, 2023. The lead plaintiff deadline is April …
Read More
Neumora Therapeutics, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before April 7, 2025 to Discuss Your Rights - NMRA
Published: February 13, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 13, 2025 / If you suffered a loss on your Neumora Therapeutics, Inc. (NASDAQ:NMRA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/neumora-therapeutics-inc-lawsuit-submission-form?prid=129366&wire=1 or contact Joseph E. Levi, Esq.
Read More
Neumora Therapeutics, Inc. Class Action Alert: Wolf Haldenstein Adler Freeman & Herz LLP reminds investors that a securities class action lawsuit has been filed in the United States District Court for the Southern District of New York against Neumora Ther
Published: February 13, 2025 by: GlobeNewsWire
Sentiment: Neutral
Lead Plaintiff Deadline is April 7, 2025 CLICK HERE TO PROVIDE CONTACT INFORMATION AND JOIN THE CASE NEW YORK, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Wolf Haldenstein Adler Freeman & Herz LLP (“Wolf Haldenstein”) announces that a securities class action lawsuit has been filed in the United States District Court for the Southern District of New York on behalf of purchasers of Neumora Therapeutics, Inc. (“Neumora”) (NASDAQ: NMRA) common stock pursuant and/or traceable to Neumora's registration statement issued in connection with Neumora's initial public offering (“IPO”) held on September 15, 2023. In its IPO, Neumora sold 14.7 million shares at …
Read More
Neumora Therapeutics, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky for More Information – NMRA
Published: February 13, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Neumora Therapeutics, Inc. ("Neumora Therapeutics, Inc." or the "Company") (NASDAQ: NMRA) of a class action securities lawsuit.
Read More
Contact Levi & Korsinsky by April 7, 2025 Deadline to Join Class Action Against Neumora Therapeutics, Inc. (NMRA)
Published: February 13, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 13, 2025 / If you suffered a loss on your Neumora Therapeutics, Inc. (NASDAQ:NMRA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/neumora-therapeutics-inc-lawsuit-submission-form?prid=129306&wire=1 or contact Joseph E. Levi, Esq.
Read More
Neumora Therapeutics, Inc. Is Being Sued For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm
Published: February 13, 2025 by: Accesswire
Sentiment: Neutral
LOS ANGELES, CA / ACCESS Newswire / February 13, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Neumora Therapeutics, Inc. ("Neumora" or "the Company") (NASDAQ:NMRA) for violations of the federal securities laws. Investors who purchased the Company's securities pursuant and/or traceable to the Company's Offering Documents in connection with its initial public offering ("IPO") conducted on September 15, 2023, are encouraged to contact the firm before April 7, 2025.
Read More
NMRA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Neumora Therapeutics, Inc. Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
Published: February 13, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 13, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Neumora Therapeutics, Inc. ("Neumora" or "the Company") (NASDAQ:NMRA) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Neumora securities pursuant to the registration statement and prospectus issued in connection with the Company's September 15, 2023 initial public offering ("IPO").
Read More
Neumora Therapeutics Announces Leadership Transition
Published: February 13, 2025 by: GlobeNewsWire
Sentiment: Neutral
Paul L. Berns, executive chair of Neumora Board of Directors, to serve as chief executive officer and chairman of the Board
Read More
Class Action Filed Against Neumora Therapeutics, Inc. (NMRA) Seeking Recovery for Investors - Contact The Gross Law Firm
Published: February 13, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Feb. 13, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Neumora Therapeutics, Inc. (NASDAQ: NMRA). Shareholders who purchased shares of NMRA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.
Read More
Investors in Neumora Therapeutics, Inc. Should Contact Levi & Korsinsky Before April 7, 2025 to Discuss Your Rights - NMRA
Published: February 13, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 13, 2025 / If you suffered a loss on your Neumora Therapeutics, Inc. (NASDAQ:NMRA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/neumora-therapeutics-inc-lawsuit-submission-form?prid=129172&wire=1 or contact Joseph E. Levi, Esq.
Read More
NMRA Investors Have Opportunity to Lead Neumora Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
Published: February 13, 2025 by: PRNewsWire
Sentiment: Neutral
LOS ANGELES , Feb. 13, 2025 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Neumora Therapeutics, Inc. ("Neumora" or "the Company") (NASDAQ: NMRA) for violations of the federal securities laws. Investors who purchased the Company's securities pursuant and/or traceable to the Company's Offering Documents in connection with its initial public offering ("IPO") conducted on September 15, 2023, are encouraged to contact the firm before April 7, 2025.
Read More
Class Action Filed Against Neumora Therapeutics, Inc. (NMRA) - April 7, 2025 Deadline to Join - Contact Levi & Korsinsky
Published: February 12, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 12, 2025 / If you suffered a loss on your Neumora Therapeutics, Inc. (NASDAQ:NMRA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/neumora-therapeutics-inc-lawsuit-submission-form?prid=129155&wire=1 or contact Joseph E. Levi, Esq.
Read More
Shareholders of Neumora Therapeutics, Inc. Should Contact Levi & Korsinsky Before April 7, 2025 to Discuss Your Rights – NMRA
Published: February 12, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 12, 2025 / If you suffered a loss on your Neumora Therapeutics, Inc. (NASDAQ:NMRA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/neumora-therapeutics-inc-lawsuit-submission-form?prid=129112&wire=1 or contact Joseph E. Levi, Esq.
Read More
The Schall Law Firm Invites Shareholders With Losses To Join A Securities Fraud Case Against Neumora Therapeutics, Inc.
Published: February 12, 2025 by: Accesswire
Sentiment: Neutral
LOS ANGELES, CA / ACCESS Newswire / February 12, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Neumora Therapeutics, Inc. ("Neumora" or "the Company") (NASDAQ:NMRA) for violations of the federal securities laws. Investors who purchased the Company's securities pursuant and/or traceable to the Company's Offering Documents in connection with its initial public offering ("IPO") conducted on September 15, 2023, are encouraged to contact the firm before April 7, 2025.
Read More
Neumora Therapeutics, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before April 7, 2025 to Discuss Your Rights - NMRA
Published: February 12, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 12, 2025 / If you suffered a loss on your Neumora Therapeutics, Inc. (NASDAQ:NMRA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/neumora-therapeutics-inc-lawsuit-submission-form?prid=129100&wire=1 or contact Joseph E. Levi, Esq.
Read More
NMRA Investors Have Opportunity to Lead Neumora Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
Published: February 12, 2025 by: Business Wire
Sentiment: Neutral
LOS ANGELES--(BUSINESS WIRE)--NMRA Investors Have Opportunity to Lead Neumora Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm.
Read More
Shareholders that lost money on Neumora Therapeutics, Inc.(NMRA) should contact The Gross Law Firm about pending Class Action - NMRA
Published: February 12, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Feb. 12, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Neumora Therapeutics, Inc. (NASDAQ: NMRA).
Read More
NMRA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Neumora Therapeutics, Inc. Stockholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
Published: February 12, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 12, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Neumora Therapeutics, Inc. ("Neumora" or "the Company") (NASDAQ:NMRA) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Neumora securities pursuant to the registration statement and prospectus issued in connection with the Company's September 15, 2023 initial public offering ("IPO").
Read More
Class Action Filed Against Neumora Therapeutics, Inc. (NMRA) - April 7, 2025 Deadline to Join - Contact Levi & Korsinsky
Published: February 11, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 11, 2025 / If you suffered a loss on your Neumora Therapeutics, Inc. (NASDAQ:NMRA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/neumora-therapeutics-inc-lawsuit-submission-form?prid=128876&wire=1 or contact Joseph E. Levi, Esq.
Read More
ROSEN, TOP-RANKED INVESTOR COUNSEL, Encourages Neumora Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - NMRA
Published: February 11, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 11, 2025 / WHY: Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of the common stock of Neumora Therapeutics, Inc.(NASDAQ:NMRA) pursuant and/or traceable to the registration statement and related prospectus (collectively, the "Offering Documents") issued in connection with Neumora's September 2023 initial public offering (the "IPO"). If you wish to serve as lead plaintiff, you must move the Court no later than April 7, 2025.
Read More
Neumora Therapeutics, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before April 7, 2025 to Discuss Your Rights - NMRA
Published: February 11, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 11, 2025 / If you suffered a loss on your Neumora Therapeutics, Inc. (NASDAQ:NMRA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/neumora-therapeutics-inc-lawsuit-submission-form?prid=128854&wire=1 or contact Joseph E. Levi, Esq.
Read More
NEUMORA THERAPEUTICS, INC. (NASDAQ: NMRA) INVESTOR ALERT: Investors With Large Losses in Neumora Therapeutics, Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights
Published: February 11, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEUMORA THERAPEUTICS, INC. (NASDAQ: NMRA) INVESTOR ALERT: Investors With Large Losses in Neumora Therapeutics, Inc. Should Contact Bernstein Liebhard LLP
Read More
NMRA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Neumora Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Published: February 11, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Feb. 11, 2025 /PRNewswire/ -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Neumora Therapeutics, Inc. ("Neumora" or "the Company") (NASDAQ: NMRA) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Neumora securities pursuant to the registration statement and prospectus issued in connection with the Company's September 15, 2023 initial public offering ("IPO").
Read More
INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of Neumora Therapeutics, Inc. (NMRA) Investors – Holzer & Holzer, LLC Encourages Investors With Significant Losses to Contact the Firm
Published: February 11, 2025 by: GlobeNewsWire
Sentiment: Neutral
ATLANTA, Feb. 11, 2025 (GLOBE NEWSWIRE) -- A securities class action lawsuit has been filed against (“Neumora” or the “Company”) (NASDAQ: NMRA) on behalf of a class of all persons or entities who purchased or otherwise acquired Neumora common stock pursuant and/or traceable to its September 15, 2023 initial public offering (the “IPO”), and who were damaged thereby. The lawsuit alleges that certain documents issued in connection with the IPO were inaccurate and misleading, contained inaccurate and misleading statements of material facts, omitted to state material facts necessary to render the statements therein not misleading, and omitted to state material …
Read More
NMRA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Neumora Therapeutics, Inc. Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
Published: February 11, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 11, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Neumora Therapeutics, Inc. ("Neumora" or "the Company") (NASDAQ:NMRA) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Neumora securities pursuant to the registration statement and prospectus issued in connection with the Company's September 15, 2023 initial public offering ("IPO").
Read More
Investors in Neumora Therapeutics, Inc. Should Contact Levi & Korsinsky Before April 7, 2025 to Discuss Your Rights - NMRA
Published: February 11, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Feb. 11, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Neumora Therapeutics, Inc. ("Neumora Therapeutics, Inc." or the "Company") (NASDAQ: NMRA) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Neumora Therapeutics, Inc. investors who were adversely affected by alleged securities fraud.
Read More
Investors who lost money on Neumora Therapeutics, Inc.(NMRA) should contact Levi & Korsinsky about pending Class Action - NMRA
Published: February 11, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 11, 2025 / If you suffered a loss on your Neumora Therapeutics, Inc. (NASDAQ:NMRA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/neumora-therapeutics-inc-lawsuit-submission-form?prid=128703&wire=1 or contact Joseph E. Levi, Esq.
Read More
Levi & Korsinsky Reminds Neumora Therapeutics, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 7, 2025 - NMRA
Published: February 11, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 11, 2025 / If you suffered a loss on your Neumora Therapeutics, Inc. (NASDAQ:NMRA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/neumora-therapeutics-inc-lawsuit-submission-form?prid=128666&wire=1 or contact Joseph E. Levi, Esq.
Read More
About Neumora Therapeutics, Inc. Common Stock (NMRA)
- IPO Date 2023-09-15
- Website https://www.neumoratx.com
- Industry Biotechnology
- CEO Dr. Daljit Singh Aurora Pharm.D.
- Employees 110